About Jimena Vicencio
Articles by Jimena Vicencio, MD
When Patients Speak, Care Improves: Older Adults Report More Severe Side Effects Than Clinical Exams ShowFeb 23, 2026
Bomedemstat for Polycythemia Vera After Standard Treatments FailFeb 11, 2026
How Can Hypomethylating Agents Improve Platelet Counts in MDS?Feb 11, 2026
Using Genetics to Eliminate Only MDS Cells with U2AF1 MutationsFeb 11, 2026
Monitoring Non-Secretory MyelomaFeb 11, 2026
Mitochondria Transplantation to Improve Transfusion-Dependent Low-Risk MDSJan 29, 2026
Avatrombopag for Platelet Recovery After Haploidentical Stem Cell TransplantJan 29, 2026
Early Results of Investigational Bispecific Antibody for Relapsed/ Refractory Multiple MyelomaJan 22, 2026
Using AI and Stem Cell Models for Targeted Treatments in MyelofibrosisJan 15, 2026
From Chemical Weapon to Chemotherapy: The History of Mustard GasJan 12, 2026
How Cancer Impacts Sexual HealthJan 12, 2026
ASH 2025: Rusfertide Shows Lasting Control of Polycythemia VeraJan 11, 2026
Improving Chronic Inflammation and Gut Health for People with MPNs: Latest ResearchJan 09, 2026
ASH 2025: Stem Cell Transplant Outcomes in MDS Have Improved Over the Last 20 YearsJan 08, 2026
Understanding Agent Orange and Cancer Risk: Lasting Health Impacts of a Global ConflictJan 08, 2026
Virtual Reality and Hypnosis May Help Ease Anxiety Before a Bone Marrow ProcedureDec 18, 2025
Can Shorter Treatment Schedules Improve Care For Lower-Risk MDS?Dec 18, 2025
Latest Research for Polycythemia Vera and MPNs: Highlights from the 2025 ASH Annual MeetingDec 17, 2025
ASH 2025 CAR T-Cell Therapy Updates: Moving Treatments to Earlier Lines of CareDec 11, 2025
Palliative Care in Blood Cancer: Meeting Patient Needs At Every StageDec 11, 2025
How Integrative Oncology Supports Your HealthDec 10, 2025
What You Need to Know About Blood Transfusions in Cancer TreatmentNov 18, 2025
U.S. FDA Approves Ziftomenib for Relapsed/Refractory AMLNov 13, 2025
The Role of Ruxolitinib Around Transplant in MyelofibrosisNov 12, 2025
